A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone
This study has been completed.
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Kirsten Herbert, Peter MacCallum Cancer Centre, Australia
First received: October 4, 2005
Last updated: May 9, 2012
Last verified: May 2012
Hematopoietic stem cells (HSC) are used to support the administration of high dose chemotherapy for a range of human cancers. For a safe HSC transplantation, a minimum of 5 million HSC per kilogram are required. HSC are collected from the bone marrow by using drugs such as G-CSF (filgrastim) which 'mobilize' them from the bone marrow into the bloodstream. HSC are collected from the bloodstream using an apheresis machine. Between 5 and 60% of patients fail to mobilize the minimum HSC dose required for safe transplantation, and this trial is investigating a way to enhance mobilization to overcome this problem. This trial aims to determine if a new vitamin A derivative is capable of enhancing HSC mobilization when used in conjunction with G-CSF. Patients will undergo two mobilization procedures. They will be given G-CSF alone, or a combination of the study drug plus G-CSF, and their stem cells will be collected. A comparison group of patients will be given G-CSF alone for both mobilizations. Stem cells collected from patients in this trial will be frozen and stored until they are required for transplantation into that patient. At that time, patients will be monitored for how well they recover from their high dose chemotherapy and HSC transplantation.
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
||A Phase I/II Study of Peripheral Blood Progenitor Cells Mobilisation With VTP195183 Plus G-CSF Compared to Mobilisation With G-CSF Alone in Patients With Multiple Myeloma and Lymphoma.
Primary Outcome Measures:
- PB CD34+ kinetics using VTP195183 plus G-CSF [ Time Frame: up to 28 days post study drug administration ]
Secondary Outcome Measures:
- The toxicity of VTP195183 pretreatment when used with G-CSF [ Time Frame: within 28 days of study drug administration ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||January 2008 (Final data collection date for primary outcome measure)
VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.
Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.
|Ages Eligible for Study:
||18 Years to 70 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Age 18-70
- Histologically proven multiple myeloma or lymphoma
- Intent of treating physician to proceed to high dose therapy and autologous transplantation
- Not currently receiving thalidomide (within 1 week of commencing VTP195813 or G-CSF), cytotoxic agents or high dose prednisolone or Dexamethasone (at doses greater than 15 mg prednisolone or equivalent per day)
- Multiple myeloma patients must be taking regular bisphosphonate therapy
- Absolute neutrophil count between 1.5 and 10 x 109/L
- ECOG performance status ? 2
- Life expectancy of at least 2 months
- Written informed consent signed by patient or legally authorized representative
- Active infection or a fever > 38.2 degrees C (fever due to B symptoms in lymphoma patients will not exclude a patient)
- Use within the previous 30 days of other vitamin A preparations within the last 30 days (including oral vitamin supplements, oral retinoids for acne or other skin disorders, bexarotene, or topical vitamin A preparations)
- Pregnancy or breast feeding. Women of child-bearing potential, admitted to the trial must take adequate measures to prevent conception (at least two different forms of contraception during the study and for at least one month after completion of study drugs) and are to undergo a pregnancy test
- Significant non-malignant disease including HIV infection, uncontrolled hypertension (diastolic blood pressures > 115 mmHg), unstable angina
- Known allergy to E.coli-derived products
- Current treatment with tetracycline antibiotics
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00234169
|Peter MacCallum Cancer centre
|Melbourne, Victoria, Australia, 3002 |
Peter MacCallum Cancer Centre, Australia
The Leukemia and Lymphoma Society
||Kirsten Herbert, MBBS
||Peter MacCallum Cancer Centre, Australia
||Kirsten Herbert, Doctor, Peter MacCallum Cancer Centre, Australia
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 4, 2005
||May 9, 2012
Keywords provided by Kirsten Herbert, Peter MacCallum Cancer Centre, Australia:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 18, 2017
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Immune System Diseases
Blood Protein Disorders
Physiological Effects of Drugs